69 related articles for article (PubMed ID: 14518215)
1. [Prognostic value of molecular biologogy and immunologic parameters in human pancreatic carcinoma].
Gansauge F; Gansauge S; Müller J; Schmid E; Beger HG
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):69-72. PubMed ID: 14518215
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of molecular alterations in human pancreatic carcinoma--an immunohistological study.
Gansauge F; Gansauge S; Schmidt E; Müller J; Beger HG
Langenbecks Arch Surg; 1998 Apr; 383(2):152-5. PubMed ID: 9641888
[TBL] [Abstract][Full Text] [Related]
3. Reduced expression of p53 and cyclin A in intraductal mucin-hypersecreting neoplasm of the pancreas compared with usual pancreatic ductal adenocarcinoma.
Mukawa K; Kawa S; Aoki Y; Zhai Y; Nikaido T
Am J Gastroenterol; 1999 Aug; 94(8):2263-7. PubMed ID: 10445560
[TBL] [Abstract][Full Text] [Related]
4. Relationship between K-ras mutation and the expression of p21WAF1/CIP1 and p53 in chronic pancreatitis and pancreatic adenocarcinoma.
Hermanová M; Lukás Z; Kroupová I; Kleibl Z; Novotný J; Nenutil R; Pazourková M; Brázdil J; Kren L; Díte P
Neoplasma; 2003; 50(5):319-25. PubMed ID: 14628083
[TBL] [Abstract][Full Text] [Related]
5. Low serum levels of CD44, CD44v6, and neopterin indicate immune dysfunction in chronic pancreatitis.
Schlosser W; Gansauge F; Schlosser S; Gansauge S; Beger HG
Pancreas; 2001 Nov; 23(4):335-40. PubMed ID: 11668200
[TBL] [Abstract][Full Text] [Related]
6. Neopterin serum levels in pancreatic adenocarcinoma.
Manes G; Spada OA; Rabitti PG; Feola B; Misso S; Minerva A; Uomo G
Int J Pancreatol; 1999 Feb; 25(1):31-7. PubMed ID: 10211419
[TBL] [Abstract][Full Text] [Related]
7. Gli1 expression in pancreatic ductal adenocarcinoma and its clinical significance.
Abula Y; Yi C; Wang XY; Wang M; Qin RY; Guo YQ; Lin H; Li HJ
Genet Mol Res; 2015 Oct; 14(4):12323-9. PubMed ID: 26505381
[TBL] [Abstract][Full Text] [Related]
8. Soluble CD44 and CD44v6 serum levels in patients with colorectal cancer are independent of tumor stage and tissue expression of CD44v6.
Weg-Remers S; Hildebrandt U; Feifel G; Moser C; Zeitz M; Stallmach A
Am J Gastroenterol; 1998 May; 93(5):790-4. PubMed ID: 9625129
[TBL] [Abstract][Full Text] [Related]
9. Induction of p21waf1 expression and growth inhibition by transforming growth factor beta involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells.
Grau AM; Zhang L; Wang W; Ruan S; Evans DB; Abbruzzese JL; Zhang W; Chiao PJ
Cancer Res; 1997 Sep; 57(18):3929-34. PubMed ID: 9307274
[TBL] [Abstract][Full Text] [Related]
10. Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma.
Saito H; Tsujitani S; Katano K; Ikeguchi M; Maeta M; Kaibara N
Cancer; 1998 Sep; 83(6):1094-101. PubMed ID: 9740073
[TBL] [Abstract][Full Text] [Related]
11. Soluble CD44 variant 6 as a prognostic indicator in patients with colorectal cancer.
Yamane N; Tsujitani S; Makino M; Maeta M; Kaibara N
Oncology; 1999 Apr; 56(3):232-8. PubMed ID: 10202279
[TBL] [Abstract][Full Text] [Related]
12. Levels of serum-soluble receptor for interleukin-2 in patients with colorectal cancer.
Saito H; Tsujitani S; Katano K; Ikeguchi M; Maeta M; Kaibara N
Surg Today; 1998; 28(10):1115-7. PubMed ID: 9786595
[TBL] [Abstract][Full Text] [Related]
13. Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers.
Tamura K; Ohtsuka T; Date K; Fujimoto T; Matsunaga T; Kimura H; Watanabe Y; Miyazaki T; Ohuchida K; Takahata S; Ishigami K; Oda Y; Mizumoto K; Nakamura M; Tanaka M
Pancreas; 2016 Jul; 45(6):826-35. PubMed ID: 26646266
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancer.
Heller A; Zörnig I; Müller T; Giorgadze K; Frei C; Giese T; Bergmann F; Schmidt J; Werner J; Buchler MW; Jaeger D; Giese NA
Cancer Immunol Immunother; 2010 Sep; 59(9):1389-400. PubMed ID: 20514540
[TBL] [Abstract][Full Text] [Related]
15. Gene Expression of Col11A1 Is a Marker Not only for Pancreas Carcinoma But also for Adenocarcinoma of the Papilla of Vater, Discriminating Between Carcinoma and Chronic Pancreatitis.
Kleinert R; Prenzel K; Stoecklein N; Alakus H; Bollschweiler E; Hölscher A; Warnecke-Eberz U
Anticancer Res; 2015 Nov; 35(11):6153-8. PubMed ID: 26504042
[TBL] [Abstract][Full Text] [Related]
16. Molecular subtypes of pancreatic cancer based on miRNA expression profiles have independent prognostic value.
Namkung J; Kwon W; Choi Y; Yi SG; Han S; Kang MJ; Kim SW; Park T; Jang JY
J Gastroenterol Hepatol; 2016 Jun; 31(6):1160-7. PubMed ID: 26644397
[TBL] [Abstract][Full Text] [Related]
17. Is hyaluronan deposition in the stroma of pancreatic ductal adenocarcinoma of prognostic significance?
Gebauer F; Kemper M; Sauter G; Prehm P; Schumacher U
PLoS One; 2017; 12(6):e0178703. PubMed ID: 28582436
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical study of genetic alterations in intraductal and invasive ductal tumors of the pancreas.
Islam HK; Fujioka Y; Tomidokoro T; Sugiura H; Takahashi T; Kondo S; Katoh H
Hepatogastroenterology; 2001; 48(39):879-83. PubMed ID: 11462947
[TBL] [Abstract][Full Text] [Related]
19. Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy.
Lechpammer M; Lukac J; Lechpammer S; Kovacević D; Loda M; Kusić Z
Int J Colorectal Dis; 2004 Mar; 19(2):114-20. PubMed ID: 14634775
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma.
Karakhanova S; Ryschich E; Mosl B; Harig S; Jäger D; Schmidt J; Hartwig W; Werner J; Bazhin AV
Br J Cancer; 2015 Mar; 112(6):1027-36. PubMed ID: 25742476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
